EP300 and prostate carcinoma: Given the scarcity of high-quality research pertaining to this issue, our ability to draw firm conclusions and uncover substantial findings regarding the potential clinical application of TMPRSS2 and p300 in the management of prostate cancer patients is influenced by bias.